1
|
Bokros M, Balukoff NC, Grunfeld A, Sebastiao M, Beurel E, Bourgault S, Lee S. RNA tailing machinery drives amyloidogenic phase transition. Proc Natl Acad Sci U S A 2024; 121:e2316734121. [PMID: 38805292 PMCID: PMC11161805 DOI: 10.1073/pnas.2316734121] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/26/2023] [Accepted: 04/18/2024] [Indexed: 05/30/2024] Open
Abstract
The RNA tailing machinery adds nucleotides to the 3'-end of RNA molecules that are implicated in various biochemical functions, including protein synthesis and RNA stability. Here, we report a role for the RNA tailing machinery as enzymatic modifiers of intracellular amyloidogenesis. A targeted RNA interference screen identified Terminal Nucleotidyl-transferase 4b (TENT4b/Papd5) as an essential participant in the amyloidogenic phase transition of nucleoli into solid-like Amyloid bodies. Full-length-and-mRNA sequencing uncovered starRNA, a class of unusually long untemplated RNA molecules synthesized by TENT4b. StarRNA consists of short rRNA fragments linked to long, linear mixed tails that operate as polyanionic stimulators of amyloidogenesis in cells and in vitro. Ribosomal intergenic spacer noncoding RNA (rIGSRNA) recruit TENT4b in intranucleolar foci to coordinate starRNA synthesis driving their amyloidogenic phase transition. The exoribonuclease RNA Exosome degrades starRNA and functions as a general suppressor of cellular amyloidogenesis. We propose that amyloidogenic phase transition is under tight enzymatic control by the RNA tailing and exosome axis.
Collapse
Affiliation(s)
- Michael Bokros
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL33136
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, Cancer Epigenetics Program, University of Miami, Miami, FL33136
| | - Nathan C. Balukoff
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL33136
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, Cancer Epigenetics Program, University of Miami, Miami, FL33136
| | - Alex Grunfeld
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL33136
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, Cancer Epigenetics Program, University of Miami, Miami, FL33136
| | - Mathew Sebastiao
- Department of Chemistry, Université du Québec à Montréal, MontrealQCH3C 3P8, Canada
- Quebec Network for Research on Protein Function, Engineering, and Applications, PROTEO, Montreal, QCH3C 3P8, Canada
| | - Eléonore Beurel
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL33136
- Department of Psychiatry and Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, FL33136
| | - Steve Bourgault
- Department of Chemistry, Université du Québec à Montréal, MontrealQCH3C 3P8, Canada
- Quebec Network for Research on Protein Function, Engineering, and Applications, PROTEO, Montreal, QCH3C 3P8, Canada
| | - Stephen Lee
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL33136
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, Cancer Epigenetics Program, University of Miami, Miami, FL33136
| |
Collapse
|
2
|
Szaflarski W, Leśniczak-Staszak M, Sowiński M, Ojha S, Aulas A, Dave D, Malla S, Anderson P, Ivanov P, Lyons SM. Early rRNA processing is a stress-dependent regulatory event whose inhibition maintains nucleolar integrity. Nucleic Acids Res 2022; 50:1033-1051. [PMID: 34928368 PMCID: PMC8789083 DOI: 10.1093/nar/gkab1231] [Citation(s) in RCA: 28] [Impact Index Per Article: 9.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/24/2020] [Revised: 11/24/2021] [Accepted: 12/02/2021] [Indexed: 01/20/2023] Open
Abstract
The production of ribosomes is an energy-intensive process owing to the intricacy of these massive macromolecular machines. Each human ribosome contains 80 ribosomal proteins and four non-coding RNAs. Accurate assembly requires precise regulation of protein and RNA subunits. In response to stress, the integrated stress response (ISR) rapidly inhibits global translation. How rRNA is coordinately regulated with the rapid inhibition of ribosomal protein synthesis is not known. Here, we show that stress specifically inhibits the first step of rRNA processing. Unprocessed rRNA is stored within the nucleolus, and when stress resolves, it re-enters the ribosome biogenesis pathway. Retention of unprocessed rRNA within the nucleolus aids in the maintenance of this organelle. This response is independent of the ISR or inhibition of cellular translation but is independently regulated. Failure to coordinately control ribosomal protein translation and rRNA production results in nucleolar fragmentation. Our study unveils how the rapid translational shut-off in response to stress coordinates with rRNA synthesis production to maintain nucleolar integrity.
Collapse
Affiliation(s)
- Witold Szaflarski
- Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland
| | - Marta Leśniczak-Staszak
- Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland
| | - Mateusz Sowiński
- Department of Histology and Embryology, Poznan University of Medical Sciences, Poznań, Poland
| | - Sandeep Ojha
- Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
- The Genome Science Institute, Boston University School of Medicine, Boston, MA, USA
| | - Anaïs Aulas
- Predictive Oncology Laboratory, Cancer Research Center of Marseille (CRCM), Inserm U1068, CNRS UMR7258, Institut Paoli-Calmettes, Aix Marseille Université, Marseille, France
| | - Dhwani Dave
- Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA, USA
| | - Sulochan Malla
- Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
- The Genome Science Institute, Boston University School of Medicine, Boston, MA, USA
| | - Paul Anderson
- Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Pavel Ivanov
- Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Boston, MA, USA
- Department of Medicine, Harvard Medical School, Boston, MA, USA
| | - Shawn M Lyons
- Department of Biochemistry, Boston University School of Medicine, Boston, MA, USA
- The Genome Science Institute, Boston University School of Medicine, Boston, MA, USA
| |
Collapse
|
3
|
Abstract
Biomolecular condensates concentrate molecules to facilitate basic biochemical processes, including transcription and DNA replication. While liquid-like condensates have been ascribed various functions, solid-like condensates are generally thought of as amorphous sites of protein storage. Here, we show that solid-like amyloid bodies coordinate local nuclear protein synthesis (LNPS) during stress. On stimulus, translationally active ribosomes accumulate along fiber-like assemblies that characterize amyloid bodies. Mass spectrometry analysis identified regulatory ribosomal proteins and translation factors that relocalize from the cytoplasm to amyloid bodies to sustain LNPS. These amyloidogenic compartments are enriched in newly transcribed messenger RNA by Heat Shock Factor 1 (HSF1). Depletion of stress-induced ribosomal intergenic spacer noncoding RNA (rIGSRNA) that constructs amyloid bodies prevents recruitment of the nuclear protein synthesis machinery, abolishes LNPS, and impairs the nuclear HSF1 response. We propose that amyloid bodies support local nuclear translation during stress and that solid-like condensates can facilitate complex biochemical reactions as their liquid counterparts can.
Collapse
|
4
|
Pesarrodona M, Jauset T, Díaz‐Riascos ZV, Sánchez‐Chardi A, Beaulieu M, Seras‐Franzoso J, Sánchez‐García L, Baltà‐Foix R, Mancilla S, Fernández Y, Rinas U, Schwartz S, Soucek L, Villaverde A, Abasolo I, Vázquez E. Targeting Antitumoral Proteins to Breast Cancer by Local Administration of Functional Inclusion Bodies. ADVANCED SCIENCE (WEINHEIM, BADEN-WURTTEMBERG, GERMANY) 2019; 6:1900849. [PMID: 31559131 PMCID: PMC6755514 DOI: 10.1002/advs.201900849] [Citation(s) in RCA: 30] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/12/2019] [Revised: 06/11/2019] [Indexed: 05/07/2023]
Abstract
Two structurally and functionally unrelated proteins, namely Omomyc and p31, are engineered as CD44-targeted inclusion bodies produced in recombinant bacteria. In this unusual particulate form, both types of protein materials selectively penetrate and kill CD44+ tumor cells in culture, and upon local administration, promote destruction of tumoral tissue in orthotropic mouse models of human breast cancer. These findings support the concept of bacterial inclusion bodies as versatile protein materials suitable for application in chronic diseases that, like cancer, can benefit from a local slow release of therapeutic proteins.
Collapse
Affiliation(s)
- Mireia Pesarrodona
- Institut de Biotecnologia i de BiomedicinaUniversitat Autònoma de BarcelonaBellaterra08193BarcelonaSpain
- CIBER de BioingenieríaBiomateriales y Nanomedicina (CIBER‐BBN)C/ Monforte de Lemos 3‐528029MadridSpain
| | - Toni Jauset
- Vall d'Hebron Institute of Oncology (VHIO)Edifici CellexHospital Vall d'Hebron08035BarcelonaSpain
- Peptomyc S.L.Edifici CellexHospital Vall d'Hebron08035BarcelonaSpain
| | - Zamira V. Díaz‐Riascos
- CIBER de BioingenieríaBiomateriales y Nanomedicina (CIBER‐BBN)C/ Monforte de Lemos 3‐528029MadridSpain
- Functional Validation & Preclinical ResearchCIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
- Drug Delivery & Targeting CIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
| | - Alejandro Sánchez‐Chardi
- Departament de Biologia EvolutivaEcologia i Ciències AmbientalsFacultat de BiologiaUniversitat de BarcelonaAv. Diagonal 64308028BarcelonaSpain
| | - Marie‐Eve Beaulieu
- Vall d'Hebron Institute of Oncology (VHIO)Edifici CellexHospital Vall d'Hebron08035BarcelonaSpain
- Peptomyc S.L.Edifici CellexHospital Vall d'Hebron08035BarcelonaSpain
| | - Joaquin Seras‐Franzoso
- Drug Delivery & Targeting CIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
| | - Laura Sánchez‐García
- Institut de Biotecnologia i de BiomedicinaUniversitat Autònoma de BarcelonaBellaterra08193BarcelonaSpain
- CIBER de BioingenieríaBiomateriales y Nanomedicina (CIBER‐BBN)C/ Monforte de Lemos 3‐528029MadridSpain
- Departament de Genètica i de MicrobiologiaUniversitat Autònoma de BarcelonaBellaterra08193BarcelonaSpain
| | - Ricardo Baltà‐Foix
- Drug Delivery & Targeting CIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
| | - Sandra Mancilla
- CIBER de BioingenieríaBiomateriales y Nanomedicina (CIBER‐BBN)C/ Monforte de Lemos 3‐528029MadridSpain
- Functional Validation & Preclinical ResearchCIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
- Drug Delivery & Targeting CIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
| | - Yolanda Fernández
- CIBER de BioingenieríaBiomateriales y Nanomedicina (CIBER‐BBN)C/ Monforte de Lemos 3‐528029MadridSpain
- Functional Validation & Preclinical ResearchCIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
- Drug Delivery & Targeting CIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
| | - Ursula Rinas
- Leibniz University of HannoverTechnical Chemistry and Life ScienceCallinstr. 530167HannoverGermany
- Helmholtz Centre for Infection ResearchInhoffenstraße 738124BraunschweigGermany
| | - Simó Schwartz
- CIBER de BioingenieríaBiomateriales y Nanomedicina (CIBER‐BBN)C/ Monforte de Lemos 3‐528029MadridSpain
- Drug Delivery & Targeting CIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
| | - Laura Soucek
- Vall d'Hebron Institute of Oncology (VHIO)Edifici CellexHospital Vall d'Hebron08035BarcelonaSpain
- Peptomyc S.L.Edifici CellexHospital Vall d'Hebron08035BarcelonaSpain
- Institució Catalana de Recerca i Estudis Avançats (ICREA)08010BarcelonaSpain
- Department of Biochemistry and Molecular BiologyUniversitat Autònoma de BarcelonaBellaterra08193BarcelonaSpain
| | - Antonio Villaverde
- Institut de Biotecnologia i de BiomedicinaUniversitat Autònoma de BarcelonaBellaterra08193BarcelonaSpain
- CIBER de BioingenieríaBiomateriales y Nanomedicina (CIBER‐BBN)C/ Monforte de Lemos 3‐528029MadridSpain
- Departament de Genètica i de MicrobiologiaUniversitat Autònoma de BarcelonaBellaterra08193BarcelonaSpain
| | - Ibane Abasolo
- CIBER de BioingenieríaBiomateriales y Nanomedicina (CIBER‐BBN)C/ Monforte de Lemos 3‐528029MadridSpain
- Functional Validation & Preclinical ResearchCIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
- Drug Delivery & Targeting CIBBIM‐NanomedicineVall d'Hebron Institut de Recerca (VHIR)Universitat Autònoma de Barcelona08035BarcelonaSpain
| | - Esther Vázquez
- Institut de Biotecnologia i de BiomedicinaUniversitat Autònoma de BarcelonaBellaterra08193BarcelonaSpain
- CIBER de BioingenieríaBiomateriales y Nanomedicina (CIBER‐BBN)C/ Monforte de Lemos 3‐528029MadridSpain
- Departament de Genètica i de MicrobiologiaUniversitat Autònoma de BarcelonaBellaterra08193BarcelonaSpain
| |
Collapse
|
5
|
Latonen L. Phase-to-Phase With Nucleoli - Stress Responses, Protein Aggregation and Novel Roles of RNA. Front Cell Neurosci 2019; 13:151. [PMID: 31080406 PMCID: PMC6497782 DOI: 10.3389/fncel.2019.00151] [Citation(s) in RCA: 97] [Impact Index Per Article: 16.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2019] [Accepted: 04/08/2019] [Indexed: 12/11/2022] Open
Abstract
Protein- and RNA-containing foci and aggregates are a hallmark of many age- and mutation-related neurodegenerative diseases. This article focuses on the role the nucleolus has as a hub in macromolecule regulation in the mammalian nucleus. The nucleolus has a well-established role in ribosome biogenesis and functions in several types of cellular stress responses. In addition to known reactions to DNA damaging and transcription inhibiting stresses, there is an emerging role of the nucleolus especially in responses to proteotoxic stress such as heat shock and inhibition of proteasome function. The nucleolus serves as an active regulatory site for detention of extranucleolar proteins. This takes place in nucleolar cavities and manifests in protein and RNA collections referred to as intranucleolar bodies (INBs), nucleolar aggresomes or amyloid bodies (A-bodies), depending on stress type, severity of accumulation, and material propensities of the macromolecular collections. These indicate a relevance of nucleolar function and regulation in neurodegeneration-related cellular events, but also provide surprising connections with cancer-related pathways. Yet, the molecular mechanisms governing these processes remain largely undefined. In this article, the nucleolus as the site of protein and RNA accumulation and as a possible protective organelle for nuclear proteins during stress is viewed. In addition, recent evidence of liquid-liquid phase separation (LLPS) and liquid-solid phase transition in the formation of nucleoli and its stress responses, respectively, are discussed, along with the increasingly indicated role and open questions for noncoding RNA species in these events.
Collapse
Affiliation(s)
- Leena Latonen
- Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
| |
Collapse
|
6
|
Wang M, Bokros M, Theodoridis PR, Lee S. Nucleolar Sequestration: Remodeling Nucleoli Into Amyloid Bodies. Front Genet 2019; 10:1179. [PMID: 31824572 PMCID: PMC6881480 DOI: 10.3389/fgene.2019.01179] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2019] [Accepted: 10/24/2019] [Indexed: 01/14/2023] Open
Abstract
This year marks the 20th anniversary of the discovery that the nucleolus can temporarily immobilize proteins, a process known as nucleolar sequestration. This review reflects on the progress made to understand the physiological roles of nucleolar sequestration and the mechanisms involved in the immobilization of proteins. We discuss how protein immobilization can occur through a highly choreographed amyloidogenic program that converts the nucleolus into a large fibrous organelle with amyloid-like characteristics called the amyloid body (A-body). We propose a working model of A-body biogenesis that includes a role for low-complexity ribosomal intergenic spacer RNA (rIGSRNA) and a discrete peptide sequence, the amyloid-converting motif (ACM), found in many proteins that undergo immobilization. Amyloid bodies provide a unique model to study the multistep assembly of a membraneless compartment and may provide alternative insights into the pathological amyloidogenesis involved in neurological disorders.
Collapse
Affiliation(s)
- Miling Wang
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, United States
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, United States
| | - Michael Bokros
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, United States
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, United States
| | - Phaedra Rebecca Theodoridis
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, United States
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, United States
| | - Stephen Lee
- Department of Biochemistry and Molecular Biology, Miller School of Medicine, University of Miami, Miami, FL, United States
- Sylvester Comprehensive Cancer Center, Miller School of Medicine, University of Miami, Miami, FL, United States
- Department of Urology, Miller School of Medicine, University of Miami, FL, United States
- *Correspondence: Stephen Lee,
| |
Collapse
|